A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.
Metastatic Renal Cell Carcinoma|Brain Metastases
DRUG: Cabozantinib|DEVICE: Nivolumab|RADIATION: Stereotactic Radiosurgery (SRS)
percent of enrolled patients who are able to tolerate treatment, 56-day safety monitoring period without unacceptable CNS toxicity. Unacceptable CNS toxicity is defined as any grade â‰¥3 treatment-emergent neurological disorder, per NCI CTCAE version 5.0 criteria, 56-day
rate of CNS adverse events, CNS adverse events will be reported as a proportion of patients who experience a CNS adverse event of any grade based on CTCAE 5.0, 1 year|objective response rate (ORR), as measured by RANO-BM criteria, 1 year
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.